Ameloblastoma secondary prevention

Ameloblastoma Microchapters
Home
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Ameloblastoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-Ray
CT
MRI
Echocardiography and Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Ameloblastoma secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Ameloblastoma secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Ameloblastoma secondary prevention
CDC on Ameloblastoma secondary prevention
Ameloblastoma secondary prevention in the news
Blogs on Ameloblastoma secondary prevention
Directions to Hospitals Treating Ameloblastoma
Risk calculators and risk factors for Ameloblastoma secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Simrat Sarai, M.D. [2]

Overview

Secondary prevention strategies following ameloblastoma include follow-up examination at regular intervals for at least 10 years.

Secondary Prevention

• Regular follow-up examination with the physician is very important in managing ameloblastoma.
• For ameloblastoma patients follow up should occur at regular intervals for at least 10 years.